Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emraclidine Bioavailability in Healthy Adults
NCT07587008Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emraclidine in schizophrenia (6 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 44 days, Maximum Observed Plasma Concentration of Emraclidine at 14 days and 2 more. Started May 2026; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07587008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587008.